About Spark Therapeutics At Spark Therapeutics, a fully integrated commercial company dedicated to the discovery, development and supply of gene therapies, we question the inevitability of genetic diseases, including blindness, hemophilia, lysosomal memory disorders and neurodegenerative diseases. We have successfully used our technology in the first gene therapy, approved in the United States and the EU for a genetic disease, and we currently have four clinical trial programs, including product candidates, that have shown promising early results in hemophilia patients. At Spark, we see the path to a world where life is not limited by genetic diseases. For more information, visit www.sparktx.com and follow us on Twitter and LinkedIn. The gene therapy company agreed in February on a merger with the Swiss pharmaceutical giant, but the conclusion has been postponed several times as competition authorities discuss the deal. “Once the merger is complete, Spark will become a wholly owned subsidiary of Roche,” Roche said. Under the merger agreement, Roche will immediately launch an offer to repurchase all of Spark`s outstanding shares, and Spark will file a statement of recommendation containing the unanimous recommendation of Spark`s board of directors that Spark`s shareholders transfer their shares to Roche. The merger between Spark Therapeutics and Roche came closer following the refurbishment of the $4.8 billion deal by the UK`s competition watchdog before a regulatory deadline in the United States later today. About Roche Roche is a global leader in drugs and diagnostics, which focuses on promoting science to improve people`s lives. The combined strengths of drugs and diagnostic medical devices under one roof have made Roche the market leader in personalized health care – a strategy that aims to provide every patient with the right treatment in the best possible way. Roche is the world`s largest biotechnology company with truly differentiated drugs in the fields of oncology, immunology, infectious diseases, ophthalmology and diseases of the central safety system. Roche is also the world leader in in vitro diagnosis and tissue diagnosis of cancer and a leader in diabetes management. Founded in 1896, Roche continues to look for better ways to prevent, diagnose and treat disease and make a lasting contribution to society.
In addition, the company aims to improve patients` access to medical innovations by working with all relevant stakeholders. Thirty drugs developed by Roche are on the World Health Organization`s model lists of essential medicines, including life-saving antibiotics, antimalarials and anti-cancer drugs. Roche was also recognized for the tenth consecutive year by the Dow Jones Sustainability Indices (DJSI) as the most sustainable company in the pharmaceutical industry. Headquartered in Basel, Switzerland, the Roche Group operates in more than 100 countries and employed approximately 94,000 people worldwide in 2018. In 2018, Roche invested chf 11 billion in research and development and generated sales of CHF 56.8 billion. Genentech in the United States is a 100% member of the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical, Japan. For more information, see www.roche.com. All trademarks used or mentioned in this press release are protected by law. IMPORTANT ADDITIONAL INFORMATION AND WHERE THERE IS THE TENDER OFFER FOR THE OUTSTANDING COMMON STOCK OF SPARK THERAPEUTICS HAS NOT STARTEDD.
THIS AD IS ONLY FOR INFORMATION PURPOSES AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR SOLICITATION OF AN OFFER TO SELL SPARK THERAPEUTICS COMMON STOCK.